Company profile
Rani Therapeutics Holdings, Inc.
NASDAQ: RANI · Healthcare · Biotechnology
#819 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
41DFH 45DQ 29GM 49SS 44
v0.1 · 65/100 weight · provisional
↑ revenue growth (YoY), balance-sheet leverage · ↓ operating margin, listing tenure
Methodology →Revenue TTM
$4.9M
Rev growth YoY (TTM)
+306.4%
Net income (FY)
-$29.7M
Employees
70
as of 2026-08-19
Market cap
$53.9M
as of 2026-08-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.6M$1.6M2025
Net income-$29.7M-$29.7M2025
Operating income-$38.3M-$38.3M2025
Total assets$58.6M$58.6M2025
Liabilities$17.1M$17.1M2025
Equity$33.0M$33.0M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Rani Therapeutics Holdings, Inc.’s revenue?
Rani Therapeutics Holdings, Inc. booked $1.6M in FY2025 revenue, growing 59% year over year — faster than most Healthcare companies we track, at a -1817.1% net margin.
Peers · Healthcare
Spectral Medical Inc31DVolitionRX Ltd40DClearside Biomedical, Inc.——EBR Systems, Inc.34DJames E. Wagner Cultivation Corporation——Cannabis Global Inc.——Neighbors
Santa Clara →Key facts
CEOTalat Imran
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Jose, CA
ExchangeNASDAQ: RANI
Employees70
IPO date2021-07-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.